Age at entry (years) Mean ± SD, [25th, 50th, 75th percentiles] | 61.7 ± 9.4, [55, 64, 69] |
---|---|
BMI (kg/m2) Mean ± SD, [25th, 50th, 75th percentiles] | 29.5 ± 4.8, [25.5, 29.0, 32.0] |
Race | 61 White (88%), 6 Black (9%), 1 Asian (1%), 1 Indian (1%) |
Gender | 36Â F (52%), 33Â M (48%) |
Diabetes | 9 Yes (13%), 60 No (87%) |
Smoke | 3 Yes (4%), 66 No (96%) |
Antihypertensive drug | 43 Yes (62%), 26 No (38%) |
HeFH | 44 Yes (64%), 25 No (36%); 25 had HeFH & no CVD (36%) |
CVD | 44 Yes (64%), 25 No (36%); 25 had CVD & no HeFH (36%) |
Both HeFH & CVD | 19 (28%) |
Statin intolerant | 46 Yes (67%), 23 No (33%) |
Medication use at entry  Taking Statin (n = 23) | Statin only, N = 13 |
Statin + ezetimibe, N = 3 | |
Statin + colesevelam, N = 1 | |
Statin + ezetimibe + colesevelam, N = 6 | |
 Not taking statin (n = 46) | Ezetimibe only, N = 2 |
Colesevelam only, NÂ =Â 2 | |
Ezetimibe + colesevelam, NÂ =Â 3 | |
Nothing, NÂ =Â 39 | |
Follow up weeks Mean ± SD, [25th, 50th, 75th %tiles] on ALI 75 mg Q2W (n = 29) | 49 ± 13, [38, 49, 59] |
on ALI 150 mg (n = 18) or EVO 140 mg (n = 22) Q2W, data pooled | 37 ± 12 [26, 33, 45] |
Total cohort (n = 69) | 42 ± 14 [30, 40, 51] |